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The present study identifies deregulated cytokines and mediators of the immune response
in the frontal cortex and cerebellum of sporadic Creutzfeldt–Jakob disease (sCJD) MM1
and VV2 subtypes compared to age-matched controls. Deregulated genes include pro-
and anti-inflammatory cytokines, toll-like receptors, colony stimulating factors, cathepsins,
members of the complement system, and members of the integrin and CTL/CTLD family
with particular regional and sCJD subtype patterns. Analysis of cytokines and mediators
at protein level shows expression of selected molecules and receptors in neurons, in
astrocytes, and/or in microglia, thus suggesting interactions between neurons and glial
cells, mainly microglia, in the neuroinflammatory response in sCJD. Similar inflammatory
responses have been shown in the tg340 sCJD MM1 mice, revealing a progressive dereg-
ulation of inflammatory mediators with disease progression. Yet, inflammatory molecules
involved are subjected to species differences in humans and mice. Moreover, inflammatory-
related cell signaling pathways NFκB/IKK and JAK/STAT are activated in sCJD and sCJD
MM1 mice. Together, the present observations show a self-sustained complex inflamma-
tory and inflammatory-related responses occurring already at early clinical stages in animal
model and dramatically progressing at advanced stages of sCJD. Considering this scenario,
measures tailored to modulate (activate or inhibit) specific molecules could be therapeutic
options in CJD.
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INTRODUCTION
Creutzfeldt–Jakob disease (CJD) is a fatal, transmissible spongi-
form encephalopathy (TSE) characterized by rapidly progressive
dementia, pyramidal symptoms, myoclonus, ataxia, and akinetic
mutism (Appleby et al., 2009). CJD may occur as a sporadic, famil-
ial, or infectious disease (sCJD, fCJD, iCJD, respectively); sCJD is
the most prevalent form (85% of cases). It is believed that the
underlying mechanism leading to prion pathogenesis is the con-
version of the cellular prion protein (PrPc) into the abnormal
disease-related form (PrPSc), which accumulates in brain (Colby
and Prusiner, 2011).
Importantly, sCJD is a heterogeneous disease and the clinico-
pathological manifestations depend on its subtype as defined by
PRNP codon 129 (Met/Met, Met/Val, or Val/Val) and PrPSc type
(type 1 or type 2). This gives rise to six main sCJD subtypes,
with MM1 and VV2 being the most common (Parchi et al., 1999;
Parchi et al., 2009), and each one manifested by particular clinical
and neuropathological traits (Parchi et al., 2012).
Cardinal neuropathological lesions are spongiform change,
neuron loss, astrogliosis, microgliosis, and PrPSc deposition
(Liberski and Ironside, 2004). Expression of pro- and anti-
inflammatory cytokines and immune response mediators is
increased in the CSF of patients with CJD (Stoeck et al.,
2006; Sharief et al., 1999) and in the brains of CJD cases and
scrapie-infected mice (Asuni et al., 2014; Campbell et al., 1994;
Tribouillard-Tanvier et al., 2009). Microglial cells are activated in
prion diseases (Sasaki et al., 1993; Szpak et al., 2006) and they
seem to be necessary for the neurotoxicity of PrPSc in vitro (Giese
et al., 1998). Moreover, inhibition of microglia proliferation can
reduce prion-related neurotoxicity and can delay the onset of the
disease in animal models (Gomez-Nicola et al., 2013). However,
microglia probably plays a dual role, as microglial depletion in
prion organotypic slices leads to increased PrPSc deposition and
prion infectivity (Falsig et al., 2008). The relationship between
PrP deposition and neuroinflammation is also obscure as reac-
tive glia and associated cytokine expression are found in close
vicinity to PrPSc deposits (Williams et al., 1997; Muhleisen et al.,
1995; Guiroy et al., 1994), but microglial activation has also been
reported in regions of synaptic loss rather than in areas of PrPSc
deposition (Cunningham et al., 2003). Nevertheless, gliosis and
cytokine overexpression seem to correlate with the severity of the
neuropathological lesions (Van et al., 2002), and scrapie-infected
models with regulated expression of cytokines lead to significant
variations of prion incubation periods and to modifications of
the timing of the appearance of clinical symptoms (Akhtar et al.,
2013; Tamgüney et al., 2008; Pasquali et al., 2006; Schultz et al.,
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2004; Thackray et al., 2004). Although microglia activation and
cytokine expression seem to be dependent on the prion type (Shi
et al., 2013), suggesting the presence of heterogeneous inflamma-
tory responses, little is known about the regional characteristics
of the inflammatory responses in different sCJD subtypes, and
practically nothing about the complexity of the inflammatory and
immune response with disease progression.
The present study was designed to (i) analyze regional dif-
ferences in the inflammatory and immune responses in the
frontal cortex and cerebellum in MM1 and VV2 sCJD subtypes,
(ii) to asses possible correlations of the inflammatory response
with neuropathological hallmarks, and (iii) to identify modifica-
tions in downstream pathways in sCJD. To further understand
inflammatory mechanisms with disease progression, PrP murine-
null mice expressing human PrP were infected with MM1 sCJD
homogenates (sCJD MM1 mice) to investigate the development
of inflammatory responses at pre-clinical and clinical stages.
MATERIALS AND METHODS
CASES AND GENERAL PROCESSING
Brain tissue was obtained from the Institute of Neuropathology
Brain Bank (HUB-ICO-IDIBELL Biobank) and the Biobank of
Hospital Clinic-IDIBAPS following the guidelines on this mat-
ter of both Spanish legislation and the local ethics committee.
Brain tissue processing and neuropathological examination of the
present cases was carried out as described before (Ansoleaga et al.,
2013; Llorens et al., 2013). Cases studied in the present work are
summarized in Table S1 in Supplementary Material.
Semi-quantitative assessment of spongiform change, neuronal
loss, astrogliosis, and microglial response in sCJD was carried out
on sections of the frontal cortex and cerebellum as previously
described (Llorens et al., 2013). Parameters were scored as fol-
lows: 0= absent, 1=mild, 2=moderate, and 3= severe. All the
biochemical studies were performed in S3 biosafety facilities. The
presence of infectious, inflammatory, metabolic, and neoplastic
diseases was discarded in the set of samples analyzed in the present
study. No correlation between post-mortem delay (between 2 and
12.5 h) or sample storage time and levels of proteins and mRNA
analyzed were observed.
CJD SUBTYPE CHARACTERIZATION
Post-mortem neuropathological examination confirmed the diag-
nosis. The analysis of the codon 129 genotype of PrP gene (Met or
Val) was performed after isolation of genomic DNA from blood
samples according to standard methods. sCJD type 1 or type 2
classification was performed by western blot profile based on PrPSc
electrophoretic mobility after proteinase K (PK) digestion.
RNA PURIFICATION
The purification of RNA of sCJD and age-matched controls was
performed using miRvana isolation kit (Ambion, USA). Then
samples were treated with RNase-free DNase set (Ambion, US) for
30 min to avoid the extraction and subsequent amplification of
genomic DNA. The concentration of each sample was determined
at 340 nm using NanoDrop 2000 spectrophotometer (Thermo Sci-
entific, USA). RNA integrity number (RIN) was verified with the
Agilent 2100 Bioanalyzer (Agilent, USA) and the threshold for
sample selection was set at RIN equal or higher than 5.5.
RETROTRANSCRIPTION REACTION
The retrotranscriptase reaction of the RNA samples was carried
out with the High Capacity cDNA Archive kit (Applied Biosystems,
US) following the protocol provided by the manufacturer and
using the Gene Amp® 9700 PCR System thermocycler (Applied
Biosystems, USA). A parallel reaction for an RNA sample was
run in the absence of reverse transcriptase to assess the degree of
contaminating genomic DNA.
RT-PCR
PCR assays were conducted in duplicate on cDNA samples
obtained from the retrotranscription reaction and diluted 1:15
in 384-well optical plates (Applied Biosystems, USA) utilizing an
ABI Prism 7900 Sequence Detection System (Applied Biosystems,
USA). Parallel amplification reactions for each sample were car-
ried out using the 20× TaqMan Gene Expression Assays (Applied
Biosystems, USA) and 2× TaqMan Universal PCR Master Mix
(Applied Biosystems, USA). The internal housekeeping gene con-
trolsβ-glucuronidase (GUSβ), X-prolyl aminopeptidase P1 (XPN-
PEP1), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
were used for normalization. The rationale on the use of RT-PCR
was based on the possibility to compare in the future the expres-
sion of specific genes in CJD with those already available from
our previous studies in Alzheimer’s disease and in Parkinson’s
disease (Garcia-Esparcia et al., 2014, and submitted manuscript).
The reactions were performed as follows: 50°C for 2 min, 95°C
for 10 min, and 40 cycles of 95°C for 15 s, and 60°C for 1 min.
TaqMan PCR data were captured using the Sequence Detector
Software (SDS version 2.1,Applied Biosystems, USA). Results were
analyzed with the double-delta cycle threshold (∆∆CT) method.
∆CT values represent normalized target gene levels with respect to
the internal control. ∆∆CT values were calculated as the ∆CT of
each test sample minus the mean ∆CT of the calibrator samples
for each target gene. The fold change was determined using the
equation 2(−∆∆CT). Mean fold change values for each group
were compared with one-way ANOVA followed by Tukey’s test
using the Statgraphics Statistical Analysis and Data Visualization
Software version 5.1. Differences between groups were consid-
ered statistically significant at *p< 0.05, **p< 0.01, ***p< 0.001.
Probes used in this study are shown in Table S2A,B in Supple-
mentary Material, respectively, for human and mouse probes. As
observed in Figure S1 in Supplementary Material, no differences in
the expression of the housekeeping genes were observed between
control, sCJD MM1 and sCJD VV2 groups, indicating lack of bias
between analyzed groups.
WESTERN BLOTTING
Human tissue was lysed in Lysis Buffer: 100 mM Tris pH 7, 100 mM
NaCl, 10 mM EDTA, 0.5% NP-40, and 0.5% sodium deoxycolate
plus protease and phosphatase inhibitors. After centrifugation at
14,000× g for 20 min at 4°C, supernatants were quantified for
protein concentration (BCA, Pierce), mixed with SDS-PAGE sam-
ple buffer, boiled, and subjected to 8–15% SDS-PAGE. Gels were
transferred onto nitrocellulose membranes and processed for spe-
cific immunodetection with the chemiluminescence method (ECL
Amersham, USA) using the indicated antibodies. Densitometries
were carried out with ImageJ software and values were normalized
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using β-actin and GAPDH. Normalized values were expressed as
the Fold change from values obtained in control samples. Sta-
tistical analysis between groups was performed with one-way
ANOVA test followed by Tukey’s test using the Statgraphics Statis-
tical Analysis and Data Visualization Software version 5.1. Differ-
ences between groups were considered statistically significant at
*p< 0.05, **p< 0.01, ***p< 0.001.
ELISA
Human IL10, IL6, and TNFα were analyzed using commercially
available ELISA kits from Peprotech according to the manufac-
turer’s instructions. Fifty micrograms of brain extracts were ana-
lyzed in triplicate for each condition. Human p-STAT1 (Tyr701)
and p-STAT3 (Tyr705) were analyzed using commercially available
InstantOneELISA kit from eBioscience according to the manu-
facturer’s instructions. One hundred fifty micrograms of brain
extracts was analyzed in duplicate for each condition. Descrip-
tive statistics were calculated for every group and molecular
subtype. Significances (p) were calculated with the SigmaStat
Version 3.1 software (Systat Software Inc.) using the Student’s
test/Mann–Whitney rank sum test, and for more than two groups
Kruskal–Wallis test was used.
sCJD MM1 MICE
The tg340 mouse line expressing about fourfold level of human
PrP M129 on a mouse PrP null background was generated as
described elsewhere (Padilla et al., 2011). Inocula were prepared
from sCJD MM1brain tissues as 10% (w/v) homogenates. Indi-
vidually identified 6–10-week-old mice were anesthetized and
inoculated with 2 mg of brain homogenate in the right parietal
lobe using a 25-gage disposable hypodermic needle (six animals
per group and time point). Mice were observed daily and the
neurological status was assessed weekly. When disease progression
was evident, or at the end of lifespan, animals were euthanized,
necropsy was performed, and the brain was removed. A part of the
brain was fixed by immersion in 10% buffered formalin to quan-
tify spongiform degeneration and perform immunohistological
procedures. The other part was frozen at -80°C to extract pro-
tein and RNA. Survival time was calculated for each isolate and
expressed as the mean of the survival day post-inoculation (dpi)
of all mice scoring positive for PrPSc. Infection rate was deter-
mined as the proportion of mice scoring positive for PrPSc from
all inoculated mice.
Every effort was made to minimize detrimental effects on
animals. All animal experiments were performed in compliance
with the French national guidelines, in accordance with the Euro-
pean Community Council Directive 86/609/EEC. The experimen-
tal protocol was approved by the INRA Toulouse/ENVT ethics
committee.
The animals were killed at pre-symptomatic (pre-clinical:
120 dpi) and symptomatic (early clinical: 160 dpi and late clinical:
183 dpi) stages. Additionally, MM1 inoculum dilutions were per-
formed to study prolonged disease times; animals were sacrificed
at 210 dpi (10−1 dilution) and 244 dpi (10−2 dilution).
PARAFFIN-EMBEDDED TISSUE BLOT
Paraffin-embedded tissue blot was carried out as described pre-
viously (Schulz-Schaeffer et al., 2000). SHa31 antibody was used
for immunodetection followed by application of an alkaline phos-
phatase labeled secondary antibody (Dako). Enzymatic activity
was revealed using NBT/BCIP substrate chromogen. For each tis-
sue sample, serial sections 4µm thick for PET blot and 2µm
for immunohistochemistry were collected onto membranes or
glass slides, respectively. This experimental design allowed the
identification of PET blot PrPSc positive regions.
IMMUNOHISTOCHEMISTRY
Paraformaldehyde-fixed, formic-acid treated,4-µm thick paraffin-
embedded sections of sCJD cases were obtained with a sliding
microtome. The sections were incubated with 2% hydrogen perox-
ide and 10% methanol for 30 min at room temperature, followed
by 5% normal serum for 2 h. Then the sections were incubated
overnight with one of the primary antibodies. After washing,
the sections were processed with the labeled streptavidin–biotin
method (Dako). Some sections were stained without the primary
antibody or with secondary antibody alone to rule out non-specific
immunoreactivity. Tissue sections were slightly counterstained
with hematoxylin.
ANTIBODIES
For immunohistochemistry, the following antibodies were
used: rabbit polyclonal antibodies against interleukin-10 (IL10,
AP52181PU-N,Acris) diluted 1/1,000; interleukin-10RA (IL10RA,
AP20308PU-N, Acris) diluted 1/50; interleukin-6 (IL6, ab6672,
Abcam) diluted 1/100; macrophage colony stimulating factor
(H300; M-CSF, sc13103 Santa Cruz) diluted 1/100; COX-2
(160107 Cayman) diluted 1/100; and mouse monoclonal anti-
bodies against TNF-α (ab1793, Abcam) diluted 1/10. For west-
ern blotting, the following antibodies were used: anti-β-actin
(A5316, Sigma) diluted 1/30,000, anti-GAPDH (9484, Abcam)
diluted 1/5,000, anti-PrP (SAF32, Cayman) diluted 1/1,000, anti-
IL10 diluted 1/500, anti-IL10RA diluted 1/500, anti-IL6 (6672,
Abcam), anti-C4a (63796, Abcam) diluted 1/2,000, anti-COX-
2 diluted 1/2,000, anti-SOD1 (NCL-SOD-1, Novocastra) diluted
1/2,000, anti-NFκB-p65 (4764, Cell Signalling) 1/1,000, anti-p-
NFκB-p65-Ser536 (3033, Cell Signalling) diluted 1/1,000, anti-
IκBα (4814, Cell Signalling) diluted 1/1,000, anti-p-STAT3-Tyr705
(9134, Cell Signalling) diluted 1/1,000, anti-STAT3 (610190, BD)
diluted 1/1,000, anti-STAT1 (sc-346, Santa Cruz) 1/1,000, and
anti-GFAP (M0761, Dako) diluted 1/5,000.
RESULTS
REGIONAL AND SUBTYPE-SPECIFIC RESPONSES OF INFLAMMATORY
MEDIATORS IN sCJD BRAIN
The astroglial activator LIF, the astroglial marker GFAP, the
microglial markers CD11b and IBA1, and the activated microglial
marker CD68 were up-regulated in sCJD cases, with increased
expression levels in the frontal cortex in MM1 and in the cerebel-
lum in VV2 cases (Figure 1). In contrast, the mRNA expression of
the oligodendrocyte marker OLIG2 was not altered in sCJD when
compared to controls. No correlation was found between expres-
sion levels of glial markers and the age of the patients (Figure S2
in Supplementary Material).
Twenty-five mRNAs including cytokines, toll-like receptors,
colony stimulating factors, cathepsins, members of the comple-
ment system, and members of the integrin and CTL/CTLD family
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FIGURE 1 | mRNA expression analysis of glial activators and markers
in sCJD is shown. RT-qPCR analysis of glial activators and markers in the
frontal cortex and cerebellum of control and sCJD MM1 and VV2
subtypes: (A) LIF, (B) GFAP, (C) CD11b, (D) IBA1, (E) CD68, and (F) OLIG2.
Values are normalized using GUS-b and GAPDH as internal controls.
Frontal cortex: control (Con, n=15), MM1 (n=15), VV2 (n=15);
cerebellum: control (Con, n=15), MM1 (n=15), VV2 (n=10). Data are
represented as the mean SEM. *p<0.05, **p<0.01, ***p<0.001 sCJD
compared with control cases; #p<0.05, ## p<0.01 sCJD VV2compared
with sCJD MM1 cases (Tukey’s post hoc test).
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Table 1 | (A) mRNA expression of inflammatory mediators in the frontal cortex (area 8) of control and sCJD subtypes MM1 and VV2. (B) mRNA
expression of inflammatory mediators in the cerebellum of control and sCJD subtypes MM1 and VV2.
ID Control sCJD MM1 sCJDVV2
F Change n F Change p n F Change p n
A. FRONTAL CORTEX
Anti-inflammatory cytokines
TGFB family
TGFB1 1.07±0.11 14 2.92±0.55 ** 15 1.82±0.17 14
TGFB2 1.05±0.10 14 2.25±0.39 ** 14 1.83±0.20 14
IL10 family
IL10 1.28±0.24 13 3.21±0.53 ** 14 2.17±0.27 15
IL10RA 1.06±0.10 14 2.95±0.53 *** 14 2.01±0.23 15
IL10RB 1.07±0.11 14 2.64±0.35 *** 14 1.58±0.15 ## 15
Pro-inflammatory cytokines
IL6 1±0.21 11 2.21±0.32 * 12 1.72±0.34 13
IL6st 1.04±0.09 14 1.46±0.13 * 14 1.17±0.08 15
IL8 1.41±0.32 14 1.78±0.67 14 0.94±0.17 14
IL1B 1.44±0.32 13 2.41±0.55 14 1.96±0.39 15
TNFA-family
TNFA 1.00±0.27 9 5.27±1.28 ** 14 2.36±0.33 # 14
TNFRSF1A 1.13±0.16 14 3.21±0.45 *** 14 2.50±0.24 ** 15
Complement system
C1QL1 1.11±0.17 14 1.48±0.19 15 1.33±0.12 14
C1QTNF7 1.13±0.18 14 1.18±0.17 15 0.82±0.08 15
C3AR1 1.10±0.12 14 5.82±0.83 *** 15 2.31±0.36 ### 14
Integrin family & CTL/CTLD superfamily
CLEC7A 1.10±0.12 14 2.90±0.56 ** 15 1.36±0.19 # 14
ITGB2 1.27±0.25 14 5.75±1.11 *** 15 3.34±0.57 15
CST7 1.55±0.43 14 2.32±0.94 15 1.30±0.30 15
CYBA 1.18±0.18 14 3.20±0.56 ** 14 1.95±0.30 15
INPP5D 1.09±0.11 14 2.93±0.71 * 15 1.58±0.19 15
TLRs
TLR4 1.05±0.08 14 2.22±0.30 * 14 1.77±0.23 15
TLR7 1.20±0.22 14 3.36±0.49 *** 14 2.24±0.37 15
Colony stimulating factors
CSF1R 1.10±0.13 14 2.60±0.47 ** 15 1.49±0.14 # 15
CSF3R 1.17±0.19 14 3.43±0.61 *** 15 1.70±0.19 ## 15
Cathepsins
CTSC 1.17±0.18 14 4.64±0.89 *** 15 2.93±0.41 14
CTSS 1.11±0.15 14 4.29±0.83 *** 15 2.47±0.46 15
B. CEREBELLUM
Anti-inflammatory cytokines
TGFB family
TGFB1 1.09±0.12 15 4.29±0.79 *** 14 3.44±0.43 * 11
TGFB2 1.05±0.09 15 2.77±0.48 ** 15 3.01±0.45 ** 11
IL10 family
IL10 1.15±0.17 15 3.05±0.77 * 13 7.67±1.40 *** ## 10
IL10RA 1.24±0.22 14 3.54±0.59 13 11.67±2.12 *** ### 11
IL10RB 1.08±0.12 14 2.92±0.36 ** 14 3.85±0.51 *** 11
(Continued)
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 198 | 5
Llorens et al. Inflammatory signature in sCJD brain
Table 1 | Continued
ID Control sCJD MM1 sCJDVV2
F Change n F Change p n F Change p n
Pro-inflammatory cytokines
IL6 1±0.23 12 1.52±0.27 14 2.35±0.54 * 9
IL6st 1.07±0.11 14 1.84±0.18 * 14 2.21±0.33 ** 11
IL8 1.33±0.27 14 3.44±0.85 * 14 1.70±0.35 10
IL1B 1.11±0.15 13 2.08±0.38 14 3.10±0.59 ** 10
TNFA-family
TNFA 1.00±0.15 14 2.20±0.43 * 13 3.84±0.66 *** # 10
TNFRSF1A 1.10±0.13 15 2.92±0.36 * 14 4.69±0.81 *** # 11
Complement system
C1QL1 1.15±0.16 15 2.07±0.34 14 2.53±0.39 ** 11
C1QTNF7 1.08±0.11 15 1.36±0.27 13 2.62±0.56 ** # 11
C3AR1 1.19±0.20 15 4.68±0.91 ** 14 8.30±1.26 *** # 10
Integrin family & CTL/CTLD superfamily
CLEC7A 1.09±0.11 14 2.13±0.45 13 3.28±0.48 *** 10
ITGB2 1.15±0.19 14 5.25±1.21 * 14 6.07±1.29 ** 11
CST7 1.30±0.26 14 1.50±0.43 15 1.97±0.46 11
CYBA 1.24±0.23 15 5.20±1.18 ** 15 6.66±0.96 *** 11
INPP5D 1.15±0.16 15 3.14±0.63 * 14 3.55±0.66 ** 11
TLRs
TLR4 1.09±0.11 15 3.73±0.61 *** 15 2.33±0.29 11
TLR7 1.17±0.22 15 3.28±0.57 * 15 5.65±1.14 *** # 10
Colony stimulating factors
CSF1R 1.07±0.10 15 2.37±0.50 14 3.83±0.68 *** 10
CSF3R 1.10±0.12 14 2.73±0.54 14 5.90±1.34 *** # 10
Cathepsins
CTSC 1.10±0.14 15 2.94±0.58 13 5.22±1.05 *** # 11
CTSS 1.06±0.09 15 3.96±0.70 ** 14 6.49±1.06 *** # 11
Data are expressed as themean SEM. * p<0.05, ** p<0.01, *** p<0.001 sCJD comparedwith control cases. #p<0.05, ##p<0.01, ###p<0.001 sCJDVV2 compared
with sCJD MM1 cases (ANOVA one-way, Tukey’s post hoc test).
were assessed in sCJD cases. In the frontal cortex of MM1 samples,
20 inflammatory mediators were up-regulated when compared
to their age-matched controls (Table 1A). In contrast, only one
gene, the TNF-α family member, was significantly statistically up-
regulated in the frontal cortex in VV2 samples when compared to
controls (Table 1A).
Regarding the cerebellum, 15 of 22 mRNAs (TGFB1, TGFB2,
IL10, IL10RB, IL6st, IL8, TNFA, TNFRSF1A, C3AR1, ITGB2,
CYBA, INPP5D, TLR4, TLR7, and CTSS) and 22 of 25 mRNAs
(all genes analyzed but IL8, CST7, and TLR4), were up-regulated
in MM1 and VV2 cases, respectively (Table 1B). In addition, values
were higher in VV2 when compared to MM1 subtype (Table 1B).
The expression levels of proteins IL10 and IL10RA were
increased in sCJD cases, as reveled with western blotting, with
major increases in the frontal cortex in MM1 cases and in the
cerebellum in VV2, thus paralleling corresponding mRNA expres-
sion values. IL6 protein expression was also increased in sCJD cases
in frontal cortex and cerebellum with significantly higher levels in
the frontal cortex of MM1 cases (Figure 2A). ELISA analysis also
showed an increase in IL6 levels in the frontal cortex of MM1 cases
and in the cerebellum of VV2 cases. TNF-α expression levels were
increased in the frontal cortex and cerebellum in MM1 and VV2
subtypes (Figure 2B).
Western blotting revealed an elevated expression of cyclooxyge-
nase 2 (COX-2) in the frontal cortex in MM1 and VV2 cases when
compared to controls (Figure 3A). The expression of superoxide
dismutase-1 (SOD1) was also increased in the frontal cortex and
cerebellum in sCJD MM1 and VV2 cases (Figure 3A). Finally,
C4-A, a subunit of the complement system involved in local
inflammation was increased in parallel with the up-regulation of
their corresponding mRNA levels (Figure 3A).
CELL-SPECIFIC LOCALIZATION OF INFLAMMATORY MEDIATORS IN
sCJD BRAIN
Very week or absent immunoreactivity with the antibodies used
to label inflammatory mediators was seen in control age-matched
brain samples processed in parallel with sCJD cases. In contrast,
IL10 immunoreactivity was seen in scattered neurons in the cere-
bral cortex, IL10 immunoreactivity was seen in scattered neurons
in the cerebral cortex, Purkinje cells, isolated Golgi cells, and cere-
bellar glomeruli. IL6 immunoreactivity was presented in hyper-
trophic astrocytes and microglia in the cerebral cortex and in the
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FIGURE 2 | Protein expression of immune mediators in sCJD is
shown. (A) Western blot analysis of IL10, IL10RA, and IL6 in the frontal
cortex and cerebellum of control, sCJD MM1, and sCJD VV2 cases. Four
representative cases are shown. GAPDH immunostaining was used to
normalize protein loading. Densitometry values of all the cases analyzed
by western blot: control (n=15), sCJD MM1 (n=15), sCJD VV2 (n=15)
show a significant increase in the expression of IL10, IL10RA, and IL6 in
MM1 and VV2 samples. *p>0.05, **p>0.005, ***p>0.001: control
compared with sCJD; #p>0.05, ##p>0.005 sCJD MM1 compared with
sCJD VV2. AU: arbitrary units. (B) ELISA of IL6 and TNFα in the frontal
cortex and cerebellum of control, sCJD MM1, and sCJD VV2 cases.
Values obtained from control (n=10), sCJD MM1 (n=10), sCJD VV2
(n=10) reveal significant increase in the expression of IL-6 and TNF-α in
frontal cortex and cerebellum in sCJD. *p>0.05, **p>0.005,
***p>0.001: control compared with sCJD; #p>0.05 sCJD MM1
compared with sCJD VV2.
white matter of the cerebellum, but neurons were negative. IL10R
was expressed mainly in microglia and IL17R in glial cells, mainly
microglia, whereas M-CSF was expressed in scattered neurons in
the cerebral cortex, and rare amorphous deposits in the cerebel-
lum. TNF-α immunoreactivity was present in scattered neurons in
the cerebral cortex, Purkinje cells in the cerebellum and glial cells,
probably microglia, in frontal cortex and cerebellum (Figure 3B).
The expression of these markers correlated with MM1 and VV2
pathology as expected.
INFLAMMATORY-LINKED CELL SIGNALING PATHWAYS IN sCJD BRAIN
Western blot analysis of members of the NFκB/IKK pathway
showed that the expression of NFκB-p65 subunit was reduced
in the cerebellum of VV2 cases, while the NFκB-p65 phospho-
rylated (activated) form was increased in the frontal cortex and
cerebellum in MM1 and VV2 cases (Figure 4A). In frontal cortex,
phospho-NFκB-p65 levels in MM1 samples were significantly
more elevated than in VV2. The expression levels of IκBα were
comparatively diminished in the cerebellum of MM1 and VV2
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FIGURE 3 | Protein expression levels and cellular distribution of
inflammatory mediators in sCJD are shown. (A) Western blotting
analysis of COX-2, SOD1, and C4-A in the frontal cortex and cerebellum in
three representative cases each for control, sCJD MM1 and sCJD VV2
cases. GAPDH immunostaining was used to normalize total protein
loading. Densitometry values of western blots result from the analysis of
15 control (Con), 15 MM1, and 15 VV2 cases. Region- and
subtype-dependent significant increased expression is found in sCJD
when compared to controls. *p>0.05, **p>0.005, ***p>0.001 control
versus sCJD; # p>0.05, ## p>0.005 sCJD MM1 versus VV2. AU: arbitrary
units. (B) Immunohistochemistry of cytokines and immune mediators in
sCJD MM1 frontal cortex (a, c, e, g, i) and cerebellum (b, d, f, h, j); a, b:
IL6; c, d: IL10; e, f: ILR10; g, h: TNF-alpha; i, j: M-CSF. Note that IL6,
IL10RA, and TNF-α are expressed in glial cells, mainly microglia, whereas
IL10, M-CSF, and TNFα are expressed in neurons. Paraffin sections, slightly
counterstained with hematoxylin. Bar=10µm.
cases, and in the frontal cortex of MM1 cases (Figure 4A). Regard-
ing the JAK/STAT pathway, ELISA analysis of phospho-STAT1 and
phospho-STAT3 in brain lysates indicated that both proteins were
phosphorylated and activated in the frontal cortex of sCJD MM1
samples. Increased expression trends were also observed in VV2
samples (Figure 4B). Total STAT1 and STAT3 levels were not mod-
ified in sCJD samples when compared to control cases (Figure 4C).
NEUROINFLAMMATORY RESPONSES IN sCJD MM1 MICE
In order to evaluate neuroinflammatory changes with disease pro-
gression, rather than changes due to MM1 or VV2 subtype, only
sCJD MM1 and no sCJD VV2 animals were used for this purpose.
PrPSc deposition was assessed using paraffin-embedded tissue blot
(PET-Blot) in brain coronal sections at the level of the thalamus
and in the cerebellum of MM1-inoculated mice at clinical stages.
PrPSc deposition was observed in cerebral neocortex, entorhinal
cortex, amygdala, hippocampus, thalamus, and, to a lesser degree,
in striatum, cerebellum, and dorsal brain stem (Figure 5A). No
PrPSc labeling was detected in control animals (data not shown).
Total PrP levels decreased in the cortex of the MM1-inoculated
mice in parallel to the appearance of clinical symptoms (160 dpi),
and they remained steady until the final stages; total PrP cerebellar
levels were not modified with disease progression (Figure 5B).
In the cortex of MM1 mice, astrogliosis, as measured by
Gfap mRNA and GFAP protein expression, was evidenced at
symptomatic but not at pre-symptomatic stages. In the cerebel-
lum, increased Gfap mRNA and GFAP protein expression was
observed at late disease stages (180 dpi) (Figures 6A,B). Lif and
Cntf mRNAs, and the activated microglial marker Iba1 mRNA,
were also up-regulated in the CJD MM1 mice (Figures 6C,D).
Microglial and astroglial activation is in agreement with mRNA
up-regulation of several cytokines and mediators of the immune
response at clinical stages measured with TaqMan PCR assays in
sCJD MM1 the cortex of mouse brain when compared to controls
(Table 2). Only IL1β was up-regulated and IL6 down-regulated
at pre-clinical stages (Table 2). Interestingly, IL1β was not up-
regulated at late stages in the CJD MM1 mice in agreement with
IL1β levels in human samples. Several cytokines and mediators
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FIGURE 4 | Activation of the inflammatory-related signaling pathways
NFκB/IKK and JAK/STAT in sCJD is shown. (A) Western blot analysis of
NFκB-p65, p-NFκB-p65, and IκBα in the frontal cortex and cerebellum of
control, sCJD MM1, and sCJD VV2 cases. Four representative cases are
shown. GAPDH immunostaining was used to normalize total protein
loading. Densitometry values of western blots result from the analysis of
15 control (Con), 15 MM1, and 15 VV2 cases. Region- and
subtype-dependent significant increased expression is found in sCJD
when compared to controls. *p>0.05, **p>0.005 control versus sCJD;
#p>0.05 sCJD MM1 versus VV2. AU: arbitrary units. (B) ELISA of p-STAT1
and p-STAT3 in the frontal cortex of control (Con), sCJD MM1 (MM1), and
sCJD VV2 (VV2) cases. Total values result from the analysis of eight
controls, eight MM1, and eight VV2 cases. (C) Western blotting of STAT1
and STAT3 in the frontal cortex of control (Con), sCJD MM1, and sCJD
VV2 cases. Three representative cases of a total of 15 cases analyzed are
shown. GAPDH immunostaining was used to normalize total protein
loading. *p>0.05, **p>0.005 control versus sCJD; #p>0.05 sCJD MM1
versus sCJD VV2. AU: arbitrary units.
were up-regulated at late stages of disease, such as Tnfa, Tnfrs1a,
C3ar1, C4b, and Tlr7, all of them also up-regulated in human
samples. However, contrary to that seen in human samples anti-
inflammatory cytokines were not up-regulated in CJD MM1 mice.
STAT3 protein expression levels were increased in the cortex
of MM1 samples at clinical stages while no significant differences
were observed in the cerebellum. However, increased levels of p-
STAT-3 were observed at pre-clinical and clinical stages in cortex
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 198 | 9
Llorens et al. Inflammatory signature in sCJD brain
A
-PrP
Con                     MM1
120  160  180  210  120  160  180  210
Con                     MM1
120  160  180  210  120  160  180  210      dpi
B CORTEX CEREBELLUM
37kDa
25kDa
20kDa
120 140 160 180 200 220
PrP - Con
PrP - MM1
0
0,25
0,5
0,75
1
1,25
1,5
120 140 160 180 200 220
PrP - Con
PrP - MM1
Pr
P 
Pr
o
te
in
 (F
old
Ch
an
ge
)
0
0.25
0.5
0.75
1
1.25
1.5
FIGURE 5 | Characterization of sCJD MM1 mice is shown. (A) PrPSc
distribution in inoculated animals as revealed by Pet-blot analysis at end
stages of the disease. Images show PrPSc labeling in the neocortex, entorhinal
cortex, amygdala, hippocampus, and thalamus, and to a lesser degree
striatum, cerebellum, and dorsal midbrain. (B) PrP expression in the cortex
and cerebellum of inoculated animals as revealed by Western-blot analysis.
Densitometry values of three animals/time point show a significant decrease
in the expression of PrP at clinical stages in the cortex of sCJD MM1 mice.
whereas minor increases were detected in the cerebellum at clinical
stages (Figure 7).
DISCUSSION
REGIONAL AND SUBTYPE-DEPENDENT NEUROINFLAMMATION IN
sCJD MM1 AND VV2, AND IN sCJD MM1 MICE
The present study has identified sustained up-regulation of
mRNAs and over-expression of corresponding proteins involving
pro-inflammatory cytokines, inflammatory mediators, and anti-
inflammatory cytokines in the cerebral cortex and cerebellum of
sCJD types MM1 and VV2 in a regional and subtype-specific
manner. Moreover, the use of sCJD MM1 mice (murine PrP-
null mice expressing human PrP infected with human sCJD
MM1 homogenates) has shown time-dependent neuroinflamma-
tion appearing at pre-clinical stages and fully developing at clinical
stages of the induced disease.
IL1β and TNF-α are principal actors in the CNS-related neu-
roinflammation processes which, through binding to their recep-
tors, induce the expression of a broad range of inflammatory
mediators, resulting in self-sustained pro-inflammatory signal-
ing (Frankola et al., 2011; Anisman et al., 2008; Griffin, 2006).
In addition, these cytokines modulate gene expression and cellu-
lar homeostasis (Cheng et al., 1994; Anisman et al., 2008). TNF-α
is up-regulated in the frontal cortex and cerebellum in sCJD MM1
and VV2. Time-course analysis in sCJD MM1 mice has shown
that TNF-α is significantly up-regulated from 160 dpi onward.
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In contrast, IL1β is up-regulated only in the cerebellum of sCJD
VV2 cases and in the cerebral cortex at early and middle stages,
decreasing thereafter in sCJD MM1 mice. Over-expression of IL1β
has been reported in several scrapie models (Brown et al., 2003)
but remains unaltered in others (Walsh et al., 2001). This apparent
contradiction may reflect differences in the time of the progres-
sion of the disease. Our data in CJD MM1 mice indicate that
IL1β is over-expressed only at pre-clinical and early clinical disease
stages, supporting a role for IL1β in the early stage of inflamma-
tory events. In this line, normal levels of IL1β mRNA in sCJD
MM1 and frontal cortex in sCJD VV2 do not rule out the pos-
sibility of a transient increase of this cytokine at earlier stages of
the biological process. TLRs are also up-regulated in sCJD and
in sCJD MM1 mice. The role of TLRs in prion infection is con-
tradictory (Spinner et al., 2008; Prinz et al., 2003), but recently,
anti-prion activity was reported for TLR agonists (Oumata et al.,
2013). Expression levels of members of the complement system
are also increased in sCJD and sCJD MM1 mice from middle
stages (160 dpi) onward; members of the complement system
may have a detrimental effect by enhancing microglial activation,
but they may also play a protective role by eliminating aggre-
gated proteins (Bonifati and Kishore, 2007; Mabbott et al., 2001).
Differences between sCJD and sCJD MM1 regarding expression
of anti-inflammatory cytokines observed here can be explained by
species differences in line with the particularities of the inflamma-
tory responses note above which depend on the prion strain and
mouse background.
A direct region- and subtype-dependent correlation is found
between the expression of glial markers and inflammatory medi-
ators, with significantly higher levels in the frontal cortex of
MM1 cases and in the cerebellum of VV2 cases. Microglia is a
major component of chronic neurodegeneration in prion diseases
(Aguzzi et al., 2013), being the main contributor to the expression
of pro-inflammatory molecules and mediators of neurotoxicity
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FIGURE 6 | Region-specific expression of glial cell markers in sCJD
MM1 mouse model is shown. (A) Western blot analysis of GFAP in the
cortex and cerebellum of control and sCJD MM1 mice at different dpi. A
10−1 inoculum dilution was performed in animals sacrificed at 210 dpi.
qPCR analysis of (B) Gfap,
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FIGURE 6 | Continued
(C) lif and Cntf, and (D) Iba1 in the cortex and cerebellum of control
and MM1-inoculated mice at different dpi. 10−1 and 10−2 inoculum
dilutions were performed in animals sacrificed at 210 and 240 dpi,
respectively. Values are normalized using Xpnpep1 as internal
controls. Between three and six animals were analyzed for each
time-point and condition. Note increased expression of these markers
with disease progression. Data are represented as the mean SEM.
*p<0.05, **p<0.01, ***p<0.001 compared with control cases
(Tukey’s post hoc test).
(Block et al., 2007). Yet regarding the subcellular localization of
the inflammatory mediators in sCJD brain, immunohistochem-
istry has revealed the expression of IL6, IL10RA, and TNF-α in
glial cells, mainly microglia, whereas IL10, M-CSF, and TNFα are
found in neurons. These results suggest interactions between neu-
rons and glial cells, mainly microglia, in the neuroinflammatory
response in sCJD.
INFLAMMATORY-RELATED CELL SIGNALING IN sCJD AND sCJD MM1
MICE
The present study has also shown activation of the inflammatory-
related cell signaling pathways NFκB/IKK and JAK/STAT in sCJD
and sCJD MM1 mice. Nuclear translocation of NFκB, indica-
tive of NFκB activation, has been described in scrapie-infected
mice (Kim et al., 1999) and sCJD (Kovacs and Budka, 2010)
whereas the JAK/STAT pathway has been reported to be activated
in scrapie-infected mice (Na et al., 2007). Activation and nuclear
translocation of NFκB and STAT promote the transcription of a
broad range of cytokines and additional inflammatory mediators
such as IL1 and IL6, thus contributing to the self-sustained pro-
inflammatory signaling and perpetuation of the inflammatory
process. In addition NFκB and STAT activation also regulate cellu-
lar homeostasis (Schindler, 2002; Mattson and Camandola, 2001)
and initiate anti-inflammatory mechanisms such as the inhibition
of IL1β processing and secretion (Greten et al., 2007). However,
other studies have reported that the NFB signaling pathway is not a
major contributor for prion disease (Julius et al., 2008). When ana-
lyzed at different time-points, the activation of these mechanisms
occurs in parallel with disease progression starting at early clini-
cal stages in the cortex (160 dpi) and at advanced stages (180 dpi)
in the cerebellum in CJD MM1 mice. This may explain transient
up-regulation of IL1β at early stages of disease followed by normal
expression at late stages of the disease in human and mouse sCJD.
In addition to pro-inflammatory mediators, up-regulation of
the astroglial activators LIF and CNTF in sCJD and in sCJD MM1
mice can induce the activation of the JAK/STAT pathway (Kisseleva
et al., 2002; Schindler, 2002), and enhance astroglial differentiation
(Rajan and McKay, 1998).
Another key mediator of neuroinflammation is COX-2, whose
promoter is activated by TNF-α and NFκB in response to pro-
inflammatory molecules (Shishodia et al., 2004). COX-2, which
converts arachidonic acid into inflammatory prostaglandins, fuels
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Table 2 | mRNA expression of inflammatory mediators in the cortex of control and sCJD MM1 at different days post-inoculation (dpi).
ID 120 dpi 160 dpi 183 dpi 210 dpi
Control CJD MM1 Control CJD MM1 Control CJD MM1 Control CJD MM1
Anti-inflammatory cytokines
Tgfb family
Tgfb1 1.00±0.06 1.30±0.21 1.51±0.36 2.62±0.48 1.38±0.19 1.82±0.33 1.20±0.13 1.55±0.12
Tgfb2 1.06±0.35 1.18±0.09 1.55±0.65 1.51±0.40 1.55±0.19 1.83±0.42 1.66±0.42 1.20±0.19
IL10 family
IL10 Undertermined
IL10ra 1.00±0.07 0.78±0.11 1.33±0.09 1.29±0.13 1.15±0.20 1.08±0.21 0.77±0.06 1.06±0.16
IL10rb 1.00±0.01 1.15±0.24 1.44±0.30 1.38±0.11 1.21±0.14 1.31±0.24 1.15±0.06 1.08±0.18
Pro-inflammatory cytokines
IL1b 1.00±0.06 2.52±0.35 * 2.01±0.43 # 6.27±0.41 ** # 1.22±0.17 $$$ 3.14±0.87 $ 0.88±0.16 $$$ 2.49±0.77 $$
IL6 1.03±0.24 0.46±0.09 * 1.17±0.04 0.47±0.06 *** 1.12±0.36 0.42±0.11 0.34±0.08 0.44±0.08
IL6st 1.00±0.08 1.03±0.07 0.89±0.03 1.00±0.14 0.95±0.16 1.22±0.13 0.88±0.27 1.03±0.10
Tn fa-family
Tnfa 1.02±0.2 1.79±0.50 2.02±0.42 ### 7.32±1.26 ** 1.23±0.05 $$$ 8.63±1.44 * 1.10±0.31 $$$ 13.76±2.89 * #
Tnfrsf1 a 1.01±0.12 1.06±0.20 0.90±0.02 1.52±0.26 0.98±0.22 1.76±0.30 0.83±0.25 1.75±0.22 *
Complement system
C1ql1 1.14±0.2 0.84±0.13 0.93±0.05 1.07±0.10 1.03±0.23 0.91±0.17 1.01±0.19 0.73±0.13
C1qtnf7 1.02±0.21 1.16±0.12 1.07±0.15 0.94±0.13 1.12±0.37 0.73±0.12 0.79±0.14 0.94±0.10
C3ar1 1.00±0.06 1.33±0.20 1.23±0.08 4.08±0.71 * 0.60±0.10 $$ 2.77±0.78 0.46±0.08 # $$$ 3.84±0.84 *
C4b 1.05±0.32 1.91±0.41 2.07±0.38 5.09±0.68 * 1.23±0.21 8.49±1.74 * # 1.11±0.33 $ 8.41±1.42 ** #
TLRs
Tlr4 1.01±0.14 1.49±0.40 1.56±0.03 2.39±0.19 * 1.35±0.27 1.64±0.27 1.57±0.41 2.03±0.31
Tlr7 1.03±0.23 1.12±0.13 1.55±0.04 2.89±0.25 ** # 1.17±0.10 3.67±0.41 ** ## 0.88±0.14 $ 4.27±0.46 *** ###
Colony stimulating factors
Csf1r 1.00±0.08 1.44±0.49 1.47±0.09 2.34±0.21 1.36±0.17 1.50±0.30 1.33±0.30 1.54±0.23
Csf3r 1.01±0.16 1.72±0.46 1.98±0.27 5.45±0.70 * ## 1.75±0.55 2.61±0.60 $ 1.31±0.38 2.35±0.50 $$
Chemokines (CC subfamily)
Ccl3 1.00±0.01 3.45±1.32 1.56±0.43 ### 27.83±4.84 ** ## 1.44±0.10 $$$ 16.85±5.78 * 0.43±0.09 $$$ † 10.75±1.47 *** $
Ccl4 1.00±0.09 5.38±1.81 5.74±1.37 # 29.78±4.37 ** ## 1.08±0.14 $$ 18.48±6.30 * 0.74±0.22 $$ 11.92±1.88 ** $
Ccl6 1.01±0.13 4.14±1.80 1.28±0.07 21.66±4.21 * ## 1.01±0.11 9.61±2.21 * $ 0.67±0.08 $ 3.07±0.77 * $$$
Data are represented as the mean SEM. *p<0.05, **p<0.01, ***p<0.001 sCJD MM1 compared with control cases at the same dpi. #p<0.05, ##p<0.01, ###p<0.001 compared with inoculated animals at the
stage of 120 dpi; $p<0.05, $$p<0.01, $$$p< 0.001 compared with inoculated animals at the stage of 160 dpi; †p<0.05 compared with inoculated animals at the stage of 183 dpi (Tukey’s post hoc test).
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FIGURE 7 | Region-specific cell signaling in sCJD MM1 mice is shown. Western blot analysis of p-STAT3, STAT3 and IκBα levels in the cerebral cortex and
cerebellum of control and sCJD MM1 mice at different dpi. Densitometry values of three animals/time point are shown.
the inflammatory process, which feeds back cytokine expres-
sion. COX-2 has been detected in neurons in sCJD (Deininger
et al., 2003) and in glial cells in scrapie-infected mice correlat-
ing with disease progression and microglial activation (Minghetti
and Pocchiari, 2007). Interestingly, COX-2 levels have also been
related to anti-inflammatory mechanisms at late stages of the
disease. The increased COX-2 expression in sCJD observed here
supports the involvement of COX-2 in prion-induced neuroin-
flammation. In contrast, increased expression of SOD1 in sCJD
cases suggests a role for this antioxidant molecule as a compo-
nent of the anti-inflammatory response, reducing the expression
of pro-inflammatory cytokines.
CONCLUDING REMARKS
The present study has shown regional and subtype-specific
patterns of neuroinflammation in sCJD MM1 and VV2, and
a modulated temporal neuroinflammatory response in sCJD
MM1 mice with disease progression involving pro- and anti-
inflammatory cytokines and variegated mediators of the immune
response, which are expressed in neurons and glial cells, mainly
microglia. The present study has also identified activation of
downstream pathways of neuroinflammatory responses involved
in nerve cell damage and regeneration. However, it is difficult to
have an idea about the specific role of these complex responses
at the terminal stages of sCJD and sCJD MM1 mice as signals
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leading to degeneration are combined with the expression of mol-
ecules favoring regeneration. However, early activation of IL1β and
decrease in IL6 at pre-clinical stages in sCJD MM1 mice seems to
be cardinal targets for therapeutic intervention. Later on, even at
early clinical stages, the exacerbation of the inflammatory response
probably needs the application of measures tailored to modu-
late (activate or inhibit) specific molecules as therapeutic options
in sCJD.
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